Cancer drug development course // Drug Repurposing

Cancer drug development course

Anti Cancer Drug Administration Course GraphicThis double module offers the opportunity for qualified practitioners involved in the administration and care of patients receiving anti-cancer drug therapies (eg chemotherapy and monoclonal antibodies), to enhance their knowledge, skills and expertise.

The teaching and learning approaches are designed to maximise the benefits of sharing knowledge and expertise both in the classroom and via online forums. Lecturers and clinical staff will facilitate the integration of theory and practice throughout the course. You are encouraged to utilise information technologies as potential sources of knowledge and learning. All programmes offer a convenient part-time format to fit around home and work commitments.

Download the course information as a PDF

Credit Accumulation and Transfer Scheme (CATS) rating

The Credit Accumulation and Transfer Scheme is a system in which you can accumulate the credits and build them towards recognised awards, if you so wish. This double module course provides 30 Level 6 (Degree level) credits.

Course Details

This double module consists of ten days taught contact time in the University (a week block and five separate study days) and five educationally led clinical practice days.

The course also requires a minimum of 300 hours of self directed study.

Assessment Methods

The module has a written assignment based around competence in practice and a practice based workbook.

Entry Requirements

  • A Diploma in Higher Education or equivalent.

tracey cutler mainor

  • A relevant professional qualification together with appropriate experience, which we'll ask you to demonstrate by presenting a portfolio of your work.

Enquiries

Our Professional Navigator, Tracey Cutler, is also on hand to offer guidance and will help you to choose which modules are best for you, taking into account your aims, professional or clinical experience, KSF requirements and your academic achievements.

Call Tracey Cutler on 0121 331 6162.

Meet Our Professional Navigator

Hello, I’m Tracey, the Professional Navigator and I am available via the Personal Development Department (PDD).

I help health and social care professionals to choose the right Continuing Professional Development (CPD) courses. Many people call me to find out which programmes can top up their diploma into a degree, or to research postgraduate options. Others need to update their skills to remain members of a professional body or to specialise in a new area.

You don’t need all your certificates to hand when you call: I’ll just find out what qualifications you have and where you’ve worked. Often, I’ll then meet you face to face so we can discuss where you want to be. I help callers find out if their training courses they’ve done at work, can count towards an award.

I can advise on the short courses we offer, which don’t bear credits but teach new workplace skills, and flexible study options. Also I help international professionals carry out qualification comparisons as part of my role in PDD.

We offer an extensive range of modules: some of our specialist courses are otherwise only available at universities in London and Scotland. Nearly all our lecturers are practising professionals who are known and respected in their fields.

You might also like

FDA Changes Position on Cancer Drug Avastin
FDA Changes Position on Cancer Drug Avastin
New Drug Development Needed in Pancreatic Cancer
New Drug Development Needed in Pancreatic Cancer

First, about dogs and cancer

by Hydrogyrophage

It turns out that there are a handful of therapeutic cancer vaccines for dogs either available or under development. Why in dogs? Because it's far easier and cheaper to move from clinical trials to the market. So it can be done entirely in a regular research lab at a university, rather than being passed among several drug development companies to share the burden of costly clinical trials for human treatments. Once you've got a good vaccine method worked out in dogs, it's cheaper to translate that research into humans than to start from scratch.

Yes, the pharma companies get rich, but

by achilles13

If it wasn't for all the money they made, they couldn't afford the billions of dollars of research and development they do every year to create better medications. Some day these same drug companies you disparage will come up with a cure for cancer and other illnesses that have plagued humans for hundreds of years.
In the 1950s, I would have been hospitalized or in jail for my condition. But, thanks to the miracle of modern medicine, I am able to lead a normal, stable and healthy life. I have no complaints. It all depends on which side of the coin you fall on.
I hear what you are saying though

Suggestiongirl

by depression_blues

I was just speaking with my pdoc a few weeks ago regarding John Falk. Solaris Entertainment is developing a film about him:
And yes, your comments about individual responses to medication/treatment is fascinating. Are you familiar with the field of Pharmacogenomics, which is the development of personalized medicine? Since the genome map was identified, pharmaceutical companies are now factoring in the genetic makeup of patients in their drug development. 30% of women, for example, who suffer from ovarian cancer do not respond to chemotherapy

Geez, i'm so embarrassed...

by DrDrew

...i thought i could hoodwink you but you're obviously too intelligent. i've been exposed...gasp!
are you kidding me?! what are you talking about?
i'm not apologizing for the pharmaceutical industry. what game are you talking about that is "fixed"? so can you actually sit there and say that there have been no advances in the past 20 years on cancer research and extending lives? since you're such a braniac, i'm sure you can spout off stats that say that people die sooner today of cancer (in general) than 10, 20, 30 years ago, right?
i'm not talking about the politics behind drug development, cancer research, etc

Choosing primary, secondary prostate cancer Tx: PSA changes, p53 gene expression, and the Gleason score can help predict the course of therapy.(Urology): An article from: Internal Medicine News
Book (International Medical News Group)

For Wisconsin companies, BIO 2014 is about making connections  — BizTimes.com (Milwaukee)
For Catalent Pharma Solutions, a leading provider of biologics drug development and delivery that has a biomanufacturing center of excellence in Madison, BIO serves two main purposes: helping to build business relationship and providing company ..

SHORT-COURSE RADIOTHERAPY EFFECTIVE FOR BONE METASTASES.: An article from: Biotech Business
Book (Worldwide Videotex)